(NASDAQ: CBIO) Crescent Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.82%.
Crescent Biopharma's earnings in 2026 is -$178,243,000.On average, 9 Wall Street analysts forecast CBIO's earnings for 2026 to be -$116,289,592, with the lowest CBIO earnings forecast at -$125,787,859, and the highest CBIO earnings forecast at -$113,127,393. On average, 9 Wall Street analysts forecast CBIO's earnings for 2027 to be -$121,458,797, with the lowest CBIO earnings forecast at -$175,340,653, and the highest CBIO earnings forecast at -$91,482,080.
In 2028, CBIO is forecast to generate -$129,665,735 in earnings, with the lowest earnings forecast at -$164,667,743 and the highest earnings forecast at -$100,466,927.